Guest Editorial FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials January 17, 2025Vol.51 No.02By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer
ACS report: Cancer mortality continues to drop despite rising incidence in women January 17, 2025Vol.51 No.02By Yiqing Wang
Guest Editorial Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires January 17, 2025Vol.51 No.02By Dan Theodorescu, Robert A. Figlin, Howard M. Sandler and Joan August
NCCN publishes patient resource on genetic testing to guide patient decisionmaking January 17, 2025Vol.51 No.02By Jacquelyn Cobb
Trials & Tribulations Chadi Nabhan: Why I wrote a book about cancer January 17, 2025Vol.51 No.02By Chadi Nabhan
Conversation with The Cancer Letter After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency January 10, 2025Vol.51 No.01By Paul Goldberg
As fire encroached, City of Hope prepared to evacuate its Duarte campus January 10, 2025Vol.51 No.01By Paul Goldberg
White House Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.” January 10, 2025Vol.51 No.01By Claire Marie Porter
Capitol Hill Pediatric cancer research cut from spending legislation at last minuteRepublicans quietly removed hard-won pediatric cancer bills January 10, 2025Vol.51 No.01By Claire Marie Porter
FreeTrials & Tribulations New colorectal cancer screening strategies must advance the standard of care January 10, 2025Vol.51 No.01By Paul J. Limburg
